Brodimoprim, a dihydrofolate reductase inhibitor, was introduced for the treatment of
common infections of upper respiratory tract such as sinusitis and exacerbation of chronic
bronchitis. It has a broad spectrum of antimicrobial activities against most Gram-positive and
-negative pathogens including some bacterial strains that are resistant to amoxicillin, a widely
used antibiotic for the indicated infections. Brodimoprim also has a favorable pharmacokinetic
profile exemplified by its long half-life and good tissue penetration.
Off-White to Pale Yellow Solid
A structural derivative of Trimethoprim (T795615). A selective dihydrofolate reductase inhibitor; diaminopyridine antibacterial agent.
ChEBI: An aminopyrimidine that is 2,4-diaminopyrimidine in which the hydrogen at position 5 has been replaced by a 4-bromo-3,5-dimethoxybenzyl group.
